home > news > detailed info

PCI Completes Acquisition of Australia-based Pharmaceutical Packaging Professionals

PCI Pharma Services

Acquisition establishes an Asia Pacific Headquarters for PCI

Philadelphia, USA – March 12, 2018. Leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) announced the completion of its acquisition of Melbourne, Australia-based Pharmaceutical Packaging Professionals (PPP). PPP is a leading provider of clinical trial manufacturing, packaging, storage and distribution services and allows PCI to offer earlier stage outsourcing services to its customers conducting trials in the region. PCI plans to establish PPP’s Melbourne, Victoria offices as its regional headquarters for Asia Pacific, led by the founder of PPP and current Senior Vice President for PCI Asia Pacific, Craig Rogers.

Australia is a preferred destination for conducting Phase 1 clinical studies and this acquisition allows PCI to provide new services in early phase clinical sterile and non-sterile drug manufacture as well as establishes a PCI depot to serve the Asia Pacific market. PPP’s logistical services include storage capability across a range of temperature conditions including Controlled Room Temperature, 2-8˚C, -20˚C, and -80˚C environments, which expands PCI’s existing capabilities in storing, packaging, and shipping Cold Chain products. Given the considerable growth in Phase I study activity in Australia and Asia Pacific countries, PPP is currently undertaking a facility expansion and upgrade to add additional storage and distribution services, labeling and packaging rooms, Grade D manufacturing capabilities and sterile-fill manufacturing for Phase II clinical studies. PCI envisions supporting additional expansion given the anticipated growth from existing and new customers conducting clinical trials in the region.

Bill Mitchell, President and CEO of PCI Pharma Services stated: “As a leading outsourced services partner, we look for ways to better support our customers in markets where they do business. Asia Pacific, including Australia, has become an important region for clinical trials and we are focused on building upon PPP’s successes to continue to support our customers’ needs throughout the drug development lifecycle. PCI is investing to be the partner of choice for our clients as they grow, evolve, and access new markets around the world.”

The addition of PPP marks PCI’s fifth company acquisition over a five-year period. In October 2017, PCI acquired Dublin-based Millmount Healthcare, broadening its geographic presence in the European Union and complementing its service network in the United Kingdom.

PCI’s growth has been driven by both strategic acquisitions and capacity expansion within its existing state-of-the-art supply network. Business demand and market opportunities have led to facility footprint expansion in both its manufacturing and clinical trial supply businesses, as well as in Cold Chain and Ultra Cold Chain infrastructure, with the addition of refrigerated storage as well as frozen and cryogenic storage. PCI’s Clinical business has expertise in supporting mid-size and emerging biopharma companies and expects to continue this focus in the APAC region. PCI has also invested in its commercial packaging business through the addition of new packaging lines, along with capital investment in its market leading Serialization and Anticounterfeiting technologies and has tripled its capacity to over 80 lines in total across its global supply network. PCI’s investments will support new capacity and capability for drug development across its global supply network.

PCI, headquartered in Philadelphia, PA, is principally owned (on behalf of its clients) by Partners Group, with partner investors Thomas H. Lee Partners and Frazier Healthcare Partners.

Lazard Middle Market LLC acted as the exclusive financial adviser to PCI for this transaction. Johnson, Winter & Slattery and Goodwin Procter LLP acted as legal counsel to PCI for the transaction. PCI engaged global professional services firm Alvarez & Marsal to provide due diligence services.

To find out more about PCI please visit

About PCI

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over four decades in the healthcare business. Leading technology and continued investment enables us to address global development needs throughout the product life cycle — from Phase I clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit or follow us on Twitter at @PCI_Social.

About Partners Group

Partners Group is a global private markets investment management firm with over EUR 62 billion (USD 74 billion) in investment programs under management in private equity, private real estate, private infrastructure and private debt. The firm manages a broad range of customized portfolios for an international clientele of institutional investors. Partners Group is headquartered in Zug, Switzerland and has offices in Denver, Houston, New York, Săo Paulo, London, Guernsey, Paris, Luxembourg, Milan, Munich, Dubai, Mumbai, Singapore, Manila, Shanghai, Seoul, Tokyo and Sydney. The firm employs over 1,000 people and is listed on the SIX Swiss Exchange (symbol: PGHN) with a major ownership by its partners and employees.

About Thomas H. Lee Partners

Thomas H. Lee Partners, L.P. (THL) is one of the world’s oldest and most experienced private equity firms. The firm invests in growth-oriented businesses, headquartered principally in North America, across three broad sectors: Consumer & Healthcare, Media & Information Services, and Business & Financial Services. Since its founding in 1974, THL has raised over $20 billion of equity capital and invested in more than 130 businesses with an aggregate purchase price of more than $150 billion. THL strives to build great companies of lasting value and generate superior investment returns.

About Frazier Healthcare Partners

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With nearly $3.4 billion total capital raised, Frazier has invested in over 170 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies. Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe. For more information about Frazier Healthcare Partners, visit the company's website at:


Chantel Richman / Carrie Lowe at BECG /
T: +44 (0)20 3697 0158 / +44 (0)1962 893 913

phone +44 (0)1495 713 633
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
Print this page
Send to a friend
News and Press Releases

Nemeras preservative-free multidose eye dropper Novelia® approved for Santens Cosopt® for Glaucoma treatments in 29 European countries

Nemera is pleased to announce that its multidose eye dropper Novelia® has been approved for the preservative-free formulation Cosopt iMulti® (20mg/ml dorzolamide + 5mg/ml timolol eye drops, solution).
More info >>

White Papers

Protein Therapeutics

Reading Scientific Services Ltd (RSSL)

More info >>

Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement